Streetbeat News

Products Services

ABOS

BBIO

BCAN

NOVN

PMN

VRAY

U.S. stocks traded slightly higher with the Dow Jones, NASDAQ, and S&P 500 all seeing gains. The NY Empire State Manufacturing Index fell by 5.5 points to a reading of +1.1 in July. ProMIS Neurosciences, BridgeBio Pharma, and Acumen Pharmaceuticals saw significant stock increases due to positive clinical trial results. Novan, ViewRay, and BYND Cannasoft Enterprises saw significant stock decreases due to asset sales and bankruptcy filings.

Portfolio Pulse from Lisa Levin

July 17, 2023 | 2:02 pm

APLS

Apellis Pharmaceuticals' stock price plunged following the observation of occlusive retinal vasculitis from the launch of its product, Syfovre.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 2:00 pm

AAPL

Apple Inc. is rumored to be using stacked battery technology for its iPhone 15 series, allowing for a 20% increase in battery capacity without increasing the phone's size. This technology is commonly used in electric vehicles. The iPhone 15 series is expected to launch in September 2023.

Portfolio Pulse from Rounak Jain

July 17, 2023 | 1:48 pm

PMN

ProMIS Neurosciences Inc. (NASDAQ:PMN) presented preclinical data at the Alzheimer's Association International Conference 2023, showcasing the potential therapeutic advantage of its lead candidate for Alzheimer's disease, PMN310. The data highlighted PMN310's ability to target toxic amyloid-beta oligomers more selectively than other antibodies. The company also presented preclinical mouse studies characterizing a computationally-derived Alzheimer's disease vaccine. In May 2023, ProMIS received FDA clearance for its Investigational New Drug application for PMN310.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 1:44 pm

IMMX

Immix Biopharma, Inc. (NASDAQ:IMMX) has reported positive interim data from its ongoing Phase 1b/2a IMMINENT-01 clinical trial for IMX-110 in combination with BeiGene's anti-PD-1 antibody tislelizumab in patients with relapsed/refractory metastatic colorectal cancer. Tumor shrinkage was observed in 75% of patients and tumor control in 25% of patients. No severe adverse events were observed, allowing for the enrollment of the next higher dose cohort. The colorectal cancer market is estimated to reach approximately $31 billion by 2025.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 1:37 pm

IONS

Scipher Medicine has entered into a multi-disease area collaboration with Ionis Pharmaceuticals. The partnership will focus on the development of precision therapeutics in disease areas including cardiovascular and CNS. Scipher will use its Spectra platform and proprietary dataset of patient molecular data to identify novel targets for specific patient populations. Ionis can advance targets identified by Scipher and both companies will identify patient subgroups more likely to benefit from therapy, potentially decreasing time to drug approval through targeted clinical trials.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 1:33 pm

CNVS

Cineverse Corp. (NASDAQ:CNVS) is expanding its strategic partnership with Amagi to leverage Amagi CONNECT, a global FAST marketplace. The partnership will allow Amagi to provide its portfolio of FAST channels to Cineverse's streaming service and add Cineverse's streaming channels to the Amagi CONNECT marketplace. This aims to bring more third-party content to Cineverse and expand its international reach. Amagi CONNECT is preferred by many FAST platforms, including LG Channels, Plex, TCL, VIDAA Free, Rakuten TV, Xiaomi, Redbox, Canela, Netgem, and more.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 1:32 pm

LLY

The Alzheimer's Association has reported that data from Eli Lilly's study on Donanemab showed a continued increase in beneficial treatment effect relative to placebo over the course of the trial. The study revealed that 60% of participants showed a slowing of decline compared to placebo.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 1:31 pm

LLY

The Alzheimer's Association has released a statement on the Phase 3 data of Donanemab, a drug developed by Eli Lilly and Company (LLY). The data shows that Donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 1:30 pm

GTLS

Chart Industries, Inc. (NYSE:GTLS) has been selected by X-Energy Reactor Company, LLC as the preferred strategic supplier of its helium circulator system for its Xe-100 high temperature gas cooled advanced modular reactor for the UK market. Chart's Howden business, acquired in 2023, will provide the helium circulators. X-energy and its strategic partner Cavendish Nuclear plan to deploy as many as 40 Xe-100 reactors in the UK from around 2030 onwards.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 1:29 pm